Amgen stock heads into ACR data week with November 11 update

Published on 11/08/2026 at 17:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock enters a week of scheduled clinical-data presentations at ACR Convergence. The program includes a late-breaking update on dazodalibep.

Amgen events for the week

Amgen will present autoimmune-disease data at ACR Convergence from November 9 through November 11.
The OASIZ-301 program showed lower systemic disease activity versus placebo at Week 48.
Amgen enters the event with third-quarter revenue growth and raised full-year expectations.

Amgen, US0311621009, Illustration mit AI erstellt.

Amgen will be in focus during the week of November 9-15, 2026, as the company presents clinical data at the American College of Rheumatology Convergence. The official announcement says the program runs from November 8 through November 11, with investor-relevant company presentations scheduled inside the coming week.

Clinical data take center stage

The most prominent appointment is a late-breaking presentation on Wednesday, November 11, at 8:45 a.m. Eastern Time. Amgen plans to present Phase 3 OASIZ-301 results for dazodalibep in adults with Sjogren's disease and moderate-to-severe systemic disease activity. The event is part of a broader portfolio program covering rare and other serious autoimmune diseases. Amgen's ACR Convergence announcement lists the presentation schedule and the associated abstracts.

The company said the OASIZ-301 study entered the event with an average baseline ESSDAI score of 10.2. At Week 48, the four-week dosing regimen produced a least-squares mean change of minus 5.6 points, compared with minus 3.8 points for placebo. The 12-week regimen produced a minus 5.2-point change. These results give investors a defined clinical milestone to monitor, although the release also describes the information as preliminary and investigative.

Financial base before presentations

Amgen's latest reported quarter provides the operating context for the pipeline update. In its November 3 release, the company said third-quarter revenue rose 8% year over year to 10.4 billion US dollars. GAAP earnings per share increased 19% to 7.08 US dollars, while non-GAAP earnings per share rose 14% to 6.45 US dollars. The company's quarterly release also reported a 47.3% non-GAAP operating margin.

Amgen expects full-year 2026 revenue of 38.9 billion to 39.7 billion US dollars and non-GAAP earnings per share of 22.90 to 23.70 US dollars. The ACR presentations therefore arrive against a backdrop of stronger commercial performance and a raised outlook, while clinical execution remains important to the longer-term pipeline case.

Amgen stock traded at 413.20 euros on Lang & Schwarz at 17:15 CET on Sunday, November 8, 2026.

Investors can follow the real-time quote of Amgen stock.